Cobas 4800高危型人乳头瘤病毒分型检测对宫颈癌筛查的价值

Role of cobas 4800 high-risk HPV test in cervical cancer screening

目的评价cobas 4800检测高危型人乳头瘤病毒(HR-HPV)在宫颈癌前病变筛查中的价值。方法门诊1074例妇女进行cobas 4800HR-HPV检测和宫颈薄层液基细胞(TCT)检查。其中,118例同时进行阴道镜、宫颈组织病理活检,106例同时进行第二代杂交捕获法(HC2)HR-HPV检测。结果 Cobas 4800HR-HPV阳性率为17.13%,TCT阳性率为5.77%。在cobas4800HR-HPV阳性妇女中,TCT阳性率为21.66%,高于阴性组的2.69%(P<0.01)。在118例病理活检中,cobas 4800HR-HPV阳性妇女中,宫颈上皮内瘤变2级以上占25.00%,亦高于阴性组2.94%(P<0.01)。Cobas 4800HR-HPV和HC2两种检验技术的阳性符合率为88.46%,阴性符合率为90.74%。结论 Cobas 4800 HR-HPV检测技术能够方便快捷地检测出HR-HPV,并区分HR-HPV 16/18和其他12种HR-HPV;其结果与HC2有较高的符合率,对宫颈癌前病变有较高应用价值。

Objective To evaluate the role of cobas 4800 HR-HPV test for cervical cancer screening. Methods Cobas 4809 HR-HPV test and thin layer of liquid based cells（TCT） examination were used to detect HR-HPV in 1074 specimens, of whom 118 cases were evaluated with colposcopy and cervical biopsy and 106 cases were evaluated by the second generation of hybrid capture method （HC2） detection at same time. Results The positive rate of cobas 4800 HR-HPV was 17. 13% ,which of TCT was 5.77%. In the patients with cobas 4800 HR-HPV test positive, the positive rate of TCT was higher than that in those with cobas 4800 HR-HPV test negative（21.66~ vs. 2.690//00） （P^0. 01）. In 118 patients with pathological biopsy,the rate above cervical intraepithelial neoplasia II was 25.00% in cobas 4800 HR-HPV test positive samples, which was higher than 2.94% in eobas 4800 HR-HPV test negative samples （P〈0. 01）. Compared to the results reported by cobas 4800 HR-HPV test and HC2,the accordance rate of HR-HPV positive detection was 88.46 % and that of negative was 89.62%. Conclusion Cobas 4800 HR-HPV test can quickly detect the HR-HPV and differentiate HPV 16/18 and other types of HR-HPV.